N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery.


OBJECTIVE N-Butyldeoxynojirimycin (NB-DNJ), an inhibitor of HIV gp120 folding, was assessed as a broadly active therapy for the treatment of HIV/AIDS. Furthermore, to reduce the effective dose necessary for antiviral activity, NB-DNJ was encapsulated inside liposomes and targeted to HIV-infected cells. METHODS Thirty-one primary isolates of HIV (including… (More)
DOI: 10.1097/QAD.0b013e32830efd96


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.